AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma

by Elana GotkineFor patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, ac

Updated on: April 28,2024

AACR: Cadonilimab plus chemo beneficial for gastric adenocarcinoma

by Elana GotkineFor patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, ac

Updated on:April 28,2024

HPV DNA identified in oral cavity of 6.2 percent of teen girls

(HealthDay)—Human papillomavirus (HPV) DNA is detected in the oral cavities of about 6.2 percent of sexually active female adolescents, according to a study published online Oct. 25 inJAMA Netwo

Updated on: May 05,2024

HPV DNA identified in oral cavity of 6.2 percent of teen girls

(HealthDay)—Human papillomavirus (HPV) DNA is detected in the oral cavities of about 6.2 percent of sexually active female adolescents, according to a study published online Oct. 25 inJAMA Netwo

Updated on:May 05,2024

Study validates first-ever predictive AI biomarker of androgen deprivation therapy benefit in prostate cancer

by University Hospitals Cleveland Medical CenterProstate cancer cells. Credit: NIH Image GalleryData from a new study published inNEJM Evidenceshows promise for personalized use of sh

Updated on: February 20,2024

Study validates first-ever predictive AI biomarker of androgen deprivation therapy benefit in prostate cancer

by University Hospitals Cleveland Medical CenterProstate cancer cells. Credit: NIH Image GalleryData from a new study published inNEJM Evidenceshows promise for personalized use of sh

Updated on:February 20,2024

A non-coding RNA lasso catches proteins in breast cancer cells

by Lisbeth Heilesen,Aarhus UniversityThe authors show that the long non-coding RNA called A-ROD (Activating Regulator Of DKK1 expression) is only functional the moment it is released from chroma

Updated on: May 20,2024

A non-coding RNA lasso catches proteins in breast cancer cells

by Lisbeth Heilesen,Aarhus UniversityThe authors show that the long non-coding RNA called A-ROD (Activating Regulator Of DKK1 expression) is only functional the moment it is released from chroma

Updated on:May 20,2024

Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say

byH. Lee Moffitt Cancer Center & Research InstituteCancer cell during cell division. Credit: National Institutes of HealthThe recent U.S. Food and Drug Administration approval of lifileucel,

Updated on: August 03,2024

Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say

byH. Lee Moffitt Cancer Center & Research InstituteCancer cell during cell division. Credit: National Institutes of HealthThe recent U.S. Food and Drug Administration approval of lifileucel,

Updated on:August 03,2024

Cancer diagnosis can be devastating, but for some it gives permission to live more radically

by Kevin Dew, Alex Broom, Chris Cunningham, Elizabeth Dennett, Kerry Chamberlain and Richard Egan,The ConversationCredit: Ivan Samkov from PexelsA diagnosis of life-limiting cancer can be overwh

Updated on: August 28,2024

Cancer diagnosis can be devastating, but for some it gives permission to live more radically

by Kevin Dew, Alex Broom, Chris Cunningham, Elizabeth Dennett, Kerry Chamberlain and Richard Egan,The ConversationCredit: Ivan Samkov from PexelsA diagnosis of life-limiting cancer can be overwh

Updated on:August 28,2024

T-DXd yields longer overall survival than T-DM1 in patients with HER2-positive metastatic breast cancer

by American Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainSecond-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with t

Updated on: February 24,2024

T-DXd yields longer overall survival than T-DM1 in patients with HER2-positive metastatic breast cancer

by American Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainSecond-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with t

Updated on:February 24,2024

Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAs compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cance

Updated on: January 04,2024

Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAs compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cance

Updated on:January 04,2024

Exploring ways to overcome cisplatin resistance and alleviate pain in cancer treatment

by Korea University College of MedicineThe study reveals that the transcription factor NANOG activates the transient receptor potential vanilloid 1 (TRPV1)—causing neuropathic pain. TRPV1 further stim

Updated on: January 07,2024

Exploring ways to overcome cisplatin resistance and alleviate pain in cancer treatment

by Korea University College of MedicineThe study reveals that the transcription factor NANOG activates the transient receptor potential vanilloid 1 (TRPV1)—causing neuropathic pain. TRPV1 further stim

Updated on:January 07,2024

Unlocking the potential of bispecific antibody-drug conjugates for targeted cancer therapy

by Frontiers JournalsCredit: Unsplash/CC0 Public DomainAntibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines

Updated on: November 09,2024

Unlocking the potential of bispecific antibody-drug conjugates for targeted cancer therapy

by Frontiers JournalsCredit: Unsplash/CC0 Public DomainAntibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines

Updated on:November 09,2024

Researchers report results in rare gynecologic cancers from DART immunotherapy trial

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of pat

Updated on: February 03,2024

Researchers report results in rare gynecologic cancers from DART immunotherapy trial

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of pat

Updated on:February 03,2024

Identifying the underlying causes of ovarian cancer

byCedars-Sinai Medical CenterSimon Gayther, PhD, professor of Biomedical Sciences, and Michelle Jones, PhD, a research scientist in the Center for Bioinformatics and Functional Genomics, led the

Updated on: January 02,2024

Identifying the underlying causes of ovarian cancer

byCedars-Sinai Medical CenterSimon Gayther, PhD, professor of Biomedical Sciences, and Michelle Jones, PhD, a research scientist in the Center for Bioinformatics and Functional Genomics, led the

Updated on:January 02,2024